About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Effect of Drug in Glucocorticoid-induced Bone Loss Treatment

by Adeline Dorcas on April 28, 2018 at 11:58 AM
Font : A-A+

Effect of Drug in Glucocorticoid-induced Bone Loss Treatment

A new study analyzes the effectiveness of drugs in reducing the glucocorticoid-induced bone loss. The findings of the study are published in the journal The Lancet Diabetes & Endocrinology.

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.

Advertisement


The study was headed by Kenneth Saag, M.D., the Jane Knight Lowe Professor of Medicine at the University of Alabama at Birmingham.

Saag and colleagues compared the monoclonal antibody denosumab against a standard treatment for glucocorticoid-induced secondary osteoporosis, the bisphosphonate risedronate. In the 12-month results of their 24-month study, they have found that denosumab was superior to risedronate, as measured by increased bone density in the lower spine.
Advertisement

"To our knowledge, ours is the first large, randomized controlled trial of denosumab in patients with glucocorticoid-induced osteoporosis who were either prevalent glucocorticoid users or newly initiating glucocorticoid therapy," they wrote. "Denosumab could be a useful addition to the treatment armamentarium for glucocorticoid-induced osteoporosis."

The double-blind study enrolled 795 patients at 79 health care centers in Europe, Latin America, Asia and North America. Of these, 505 were glucocorticoid-continuing patients who had received glucocorticoids for at least three months, and 290 were glucocorticoid-initiating patients who had received glucocorticoids for less than three months.

Patients were randomly assigned to one of two groups. The denosumab group got a shot of denosumab underneath the skin every six months and took a placebo pill every day. The risedronate group got a placebo shot every six months and took oral risedronate every day.

Besides the superior lumbar spine bone density with denosumab after 12 months, researchers also found that denosumab was superior to risedronate for bone density measured in the total hip and at the neck of the femur, the large bone of the thigh.

The two treatment groups had similar safety profiles.

The researchers note that the study compared denosumab with risedronate, so the relative performance of denosumab compared with osteoporosis treatments besides risedronate has not yet been established.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Infantile Cortical Hyperostosis Signature Drug Toxicity Drugs Banned in India Renal Osteodystrophy / Mineral Bone Disorder Osteolysis 

Recommended Reading
Osteoporosis
Osteoporosis is a bone disease that leads to an increased risk of fractures. The bone mass is ......
Lifestyle And Osteoporosis
Encyclopedia section of medindia briefly explains about Lifestyle and Osteoporosis...
Boost Bone Health in 12 Simple Ways
More than 6 cups of coffee a day may harm bone health. Fish and olive oil may increase bone ......
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Infantile Cortical Hyperostosis
Infantile Cortical Hyperostosis is a disease of unknown cause, where bizarre thickening of the corti...
Osteolysis
Osteolysis refers to breaking down of bone tissue. Bone loss occurs due to resorption of bone by ost...
Renal Osteodystrophy / Mineral Bone Disorder
Renal Osteodystrophy which is referred to as Mineral Bone Disorder is a result of imbalance in calci...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use